EA201591683A1 - Способы лечения, снижения частоты и/или профилактики ишемических событий - Google Patents

Способы лечения, снижения частоты и/или профилактики ишемических событий

Info

Publication number
EA201591683A1
EA201591683A1 EA201591683A EA201591683A EA201591683A1 EA 201591683 A1 EA201591683 A1 EA 201591683A1 EA 201591683 A EA201591683 A EA 201591683A EA 201591683 A EA201591683 A EA 201591683A EA 201591683 A1 EA201591683 A1 EA 201591683A1
Authority
EA
Eurasian Patent Office
Prior art keywords
frequency
methods
ischemic event
patient
treating
Prior art date
Application number
EA201591683A
Other languages
English (en)
Other versions
EA034550B1 (ru
Inventor
Клив Артур Аркулус-Минвелл
Симона Скержанек
Джейн Пратс
Дэвид Дж. Шнейдер
Original Assignee
Зе Медисинс Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/792,056 external-priority patent/US9427448B2/en
Application filed by Зе Медисинс Компани filed Critical Зе Медисинс Компани
Publication of EA201591683A1 publication Critical patent/EA201591683A1/ru
Publication of EA034550B1 publication Critical patent/EA034550B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Способы лечения, снижения частоты и/или профилактики ишемического события у пациента, подвергаемого чрескожной коронарной ангиопластике (PCI), включающий введение пациенту фармацевтической композиции, содержащей кангрелор. Способ может дополнительно включать введение пациенту дополнительного терапевтического средства, где дополнительное терапевтическое средство содержит ингибитор P2Y. Фармацевтические композиции, пригодные для лечения, снижения частоты и/или профилактики ишемического события у пациента, подвергаемого PCI. Фармацевтические композиции содержат кангрелор. Способы получения фармацевтической композиции для лечения, снижения частоты и/или профилактики ишемического события у пациента, подвергаемого PCI, включающие смешивание кангрелора с одним или несколькими фармацевтически приемлемыми эксципиентами. Ишемическое событие может включать тромбоз стента, инфаркт миокарда, обусловленную ишемией реваскуляризацию и смертельный исход.
EA201591683A 2013-03-09 2013-05-29 Способы лечения, снижения частоты и/или профилактики ишемических событий EA034550B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/792,056 US9427448B2 (en) 2009-11-11 2013-03-09 Methods of treating, reducing the incidence of, and/or preventing ischemic events
US201361815735P 2013-04-25 2013-04-25
PCT/US2013/043136 WO2014143107A1 (en) 2013-03-09 2013-05-29 Methods of treating, reducing the incidence of, and/or preventing ischemic events

Publications (2)

Publication Number Publication Date
EA201591683A1 true EA201591683A1 (ru) 2016-08-31
EA034550B1 EA034550B1 (ru) 2020-02-19

Family

ID=51537409

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591683A EA034550B1 (ru) 2013-03-09 2013-05-29 Способы лечения, снижения частоты и/или профилактики ишемических событий

Country Status (10)

Country Link
EP (2) EP3978002A1 (ru)
JP (3) JP6247708B2 (ru)
CN (2) CN106102750A (ru)
AU (1) AU2013381855B2 (ru)
BR (1) BR112015022070B1 (ru)
CA (1) CA2904523C (ru)
EA (1) EA034550B1 (ru)
ES (1) ES2904256T3 (ru)
PL (1) PL2964233T3 (ru)
WO (1) WO2014143107A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3060345A1 (en) * 2017-06-23 2018-12-27 Chiesi Farmaceutici S.P.A. Method of preventing of systemic-to-pulmonary-artery shunt thrombosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE159950T1 (de) 1993-02-10 1997-11-15 Astra Pharma Prod N-alkyl-2-substituierte atp-analoge
SE9604795D0 (sv) 1996-12-20 1996-12-20 Astra Pharma Prod New pharmaceutical formulation
SE9702680D0 (sv) 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
SE9904377D0 (sv) 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
US9427448B2 (en) * 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2009140092A1 (en) * 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20100297675A1 (en) * 2008-11-24 2010-11-25 Huayun Deng Substrate and method for culturing breast cells
EA028885B1 (ru) * 2009-11-11 2018-01-31 Чиези Фармачеутичи С.П.А. Способы лечения или предотвращения тромбоза стента и инфаркта миокарда (варианты)

Also Published As

Publication number Publication date
JP2018002739A (ja) 2018-01-11
EP2964233A4 (en) 2016-10-19
BR112015022070A2 (pt) 2017-07-18
EP3978002A1 (en) 2022-04-06
EP2964233B1 (en) 2021-12-15
JP2016510738A (ja) 2016-04-11
ES2904256T3 (es) 2022-04-04
CA2904523C (en) 2024-01-09
AU2013381855B2 (en) 2018-08-02
EP2964233A1 (en) 2016-01-13
AU2013381855A1 (en) 2015-10-22
JP6247708B2 (ja) 2017-12-13
CA2904523A1 (en) 2014-09-18
WO2014143107A1 (en) 2014-09-18
PL2964233T3 (pl) 2022-04-25
CN115120606A (zh) 2022-09-30
EA034550B1 (ru) 2020-02-19
BR112015022070B1 (pt) 2022-01-18
CN106102750A (zh) 2016-11-09
JP2019178177A (ja) 2019-10-17
JP6840197B2 (ja) 2021-03-10

Similar Documents

Publication Publication Date Title
CL2023000846A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
MX2016008201A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
BR112018001640A2 (pt) combinação de antagonista da pd-1 com um inibidor de egfr
MX2019008696A (es) Compuestos de piridina como inhibidores de shp2 alostericos.
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
BR112016011949A2 (pt) Composto, composição farmacêutica, e, uso dos mesmos”
EA201690980A1 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
MX2015012760A (es) Composicion farmaceutica que comprende un activador de ampk y un agente serotonergico y metodos de uso de la misma.
EA201490254A1 (ru) Комбинированное лечение гепатита с
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
EA201391286A1 (ru) Лечение солидных опухолей
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
BR112016000335A8 (pt) método de tratamento da rosácea papulopustular, de tratamento de lesões inflamatórias da rosácea papulopustular e uso de uma composição farmacêutica
RU2018135973A (ru) Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака
WO2014179154A3 (en) Novel compounds that are erk inhibitors
WO2015095838A3 (en) Cancer treatments using combinations of mek type i and erk inhibitors
RU2018107930A (ru) Агонисты tlr4, их композиции и применение для лечения рака
WO2014186623A3 (en) Methods and compositions for the treatment of a chagas disease
BR112022019914A2 (pt) Coadministração de mirdametinibe e lifirafenibe para uso no tratamento de cânceres
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
BR112019007863A2 (pt) derivados de naftiridinona inovadores e seu uso no tratamento de arritmia
MX2019002121A (es) Tratamiento conjunto para tratar el cancer de pancreas.